NewAmsterdam Pharma stock
NAMSNASDAQNewAmsterdam Pharma Company N.V., HealthcareISIN NL00150012L7
35Score 35 out of 100, Weak
Price and trend
42 / 100
Price history
−48% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 32% below it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 52% below its 52-week high. Largest decline in 6 years: 66% (January 2023 to October 2023).
Chart figures for advanced users
- SMA 50$21.64
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$29.21
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.89
- The lowest closing price of the last twelve months.
- Resistance$41.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- NewAmsterdam Pharma Company N.V. belongs to the Biotechnology industry (Netherlands) and, with a market value of $2.4B, is number 111 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $22.5M (down 50.6% year on year) and a loss of $203.82M.
- For fiscal 2026, analysts expect on average revenue of $40.04M (up 77.9%) and adjusted earnings per share of −$1.54.
Show more
- MEQIRI Score 35 out of 100 (Weak): rank 613 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $628.24M, financial debt $76K.Stability 75
Weaknesses
- Loss-makingLoss of $204.89M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$150.86M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 50% over the last 12 months.Momentum 22
Its standout strength is stability, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
One-off effect in revenue
In the quarter to 30 Sep 2026, revenue of $19.16M was about 6 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 50.6% on the prior year. Revenue turned from negative at the start of the period to positive ($22.5M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −1003%, net −906%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 17 Feb 2027in 96 days
- Last reported
- 4 Nov 2026EPS reported −$0.14 (expected −$0.47)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 24.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.54+18.4%
- Revenue
- $40.04M+32.3%
- Earnings per share
- −$1.94−24.6%
- Revenue
- $67.46M−56.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $226,500 in total. 3 insiders sold, $11.38M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kastelein Johannes Jacob PieterSale
30 Sept 2026, Chief Scientific Officer
- Shares
- 50,246
- Price
- $25.03
- Value
- $1.26M
- Davidson Michael H.Purchase
14 Sept 2026, Chief Executive Officer
- Shares
- 10,000
- Price
- $22.65
- Value
- $226,500
- Smither John WSale
4 Sept 2026, Board
- Shares
- 1,600
- Price
- $25.32
- Value
- $40,512
Show 4 more
- Kastelein Johannes Jacob PieterSale
24 Aug 2026, Chief Scientific Officer
- Shares
- 125,000
- Price
- $26.91
- Value
- $3.36M
- Kooij Louise FrederikaSale
20 Jul 2026, Chief Accounting Officer
- Shares
- 105,000
- Price
- $30.34
- Value
- $3.19M
- Kooij Louise FrederikaSale
22 Jun 2026, Chief Accounting Officer
- Shares
- 40,000
- Price
- $30.20
- Value
- $1.21M
- Kooij Louise FrederikaSale
26 May 2026, Chief Accounting Officer
- Shares
- 65,000
- Price
- $35.69
- Value
- $2.32M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at NewAmsterdam Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- MBX BiosciencesMBX $2.71B46
- Bavarian NordicBAVA.CO $2.7B71
- Arcus BiosciencesRCUS $2.56B30
- Beam TherapeuticsBEAM $2.49B38
- PharvarisPHVS $2.38B44
- Zealand PharmaZEAL.CO $2.37B59
- Replimune GroupREPL $2.31B42
- Lakefront BiotherapeuticsLKFT $2.26B74
ETFs that hold NewAmsterdam Pharma
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.14% | 0.35% | €1.25B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
Show 4 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.